Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial
about
Mesenchymal stem cell therapy in type 2 diabetes mellitus.Adipose stem cell-based regenerative medicine for reversal of diabetic hyperglycemia.Transplantation of human fetal pancreatic progenitor cells ameliorates renal injury in streptozotocin-induced diabetic nephropathy.Human limbal fibroblast-like stem cells induce immune-tolerance in autoreactive T lymphocytes from female patients with Hashimoto's thyroiditis.Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.Stem cell transplantation improves aging-related diseasesThe role and potential of umbilical cord blood in an era of new therapies: a reviewThe aged nonhematopoietic environment impairs natural killer cell maturation and function.Hair regrowth in alopecia areata patients following Stem Cell Educator therapy.Modulation of Autoimmune T-Cell Memory by Stem Cell Educator Therapy: Phase 1/2 Clinical Trial.Mesenchymal stem cells protect against the tissue fibrosis of ketamine-induced cystitis in rat bladder.Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes.CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?The potential of cell-based therapy for diabetes and diabetes-related vascular complications.Exocytosis proteins as novel targets for diabetes prevention and/or remediation?Platelet-Derived Mitochondria Display Embryonic Stem Cell Markers and Improve Pancreatic Islet β-cell Function in Humans.
P2860
Q33691629-2808B30E-BD1F-4ACE-A37B-C3313A21213FQ33759539-5BCD7F28-9156-47DD-97E5-DE6048DC3727Q33846336-A2FCA521-03BE-42BD-9423-8C28B6AA4BB2Q33868555-69EA5E29-3E8E-4936-A898-FA5F1B358FFDQ34201551-E1EE5A45-E37A-40C6-B66D-560BB2CDD976Q34391056-7B3E297C-08B2-4475-8ABB-0CAB326ECF77Q34483172-870E340A-AED2-48E8-A892-EF9809F31F4FQ35192120-11646443-FB97-4645-8733-37E1C0D8F289Q35562516-76346F8F-EA69-4593-AB8C-A13051C5900DQ36437615-2B150B0C-B9F7-4A31-A61D-0F6695BA2091Q37144581-D6980396-F998-4628-ACA3-B00D084D163FQ37204124-283722DC-3094-412B-8816-DD3B4F788B76Q37692502-F8FD4C15-897A-4499-9A11-AD3C41825C1EQ38181982-B52F78AD-DD11-47BD-9325-711A4FF3E6DAQ39207341-B6FC12AA-FC52-49A9-B5F7-0CAD4E0AC267Q45816606-14989EC5-7FC5-4B7F-A1DA-6DC29334F5B9
P2860
Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting insulin resistance i ...... apy: phase I/II clinical trial
@ast
Targeting insulin resistance i ...... apy: phase I/II clinical trial
@en
Targeting insulin resistance i ...... derived multipotent stem cells
@nl
type
label
Targeting insulin resistance i ...... apy: phase I/II clinical trial
@ast
Targeting insulin resistance i ...... apy: phase I/II clinical trial
@en
Targeting insulin resistance i ...... derived multipotent stem cells
@nl
prefLabel
Targeting insulin resistance i ...... apy: phase I/II clinical trial
@ast
Targeting insulin resistance i ...... apy: phase I/II clinical trial
@en
Targeting insulin resistance i ...... derived multipotent stem cells
@nl
P2093
P2860
P921
P356
P1433
P1476
Targeting insulin resistance i ...... apy: phase I/II clinical trial
@en
P2093
Chengjin Hu
Hatim Thaker
Huimin Zhou
Mary Beth Fisk
Mingliang Ye
Shanfeng Wang
Summit Jain
Tingbao Zhao
P2860
P2888
P356
10.1186/1741-7015-11-160
P407
P577
2013-07-09T00:00:00Z
P5875
P6179
1005757290